Search research articles
Contact Us
Filters
Showing results (71-80 of 78) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 78 results.
Signal Transduction and Targeted Therapy
|
October 5, 2025
Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial
Kang Wang, Jinkai Feng, Hongming Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2024
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Yajin Chen, Chengyou Du, Shunli Shen, et al.
Oncogene
|
February 13, 2024
Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC
Tuo Deng, Jungang Zhao, Yifan Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2023
Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Zhiyuan Bo, Bo Chen, Zhengxiao Zhao, et al.
JCI Insight
|
May 23, 2024
PFKFB3 controls acinar IP3R-mediated Ca2+ overload to regulate acute pancreatitis severity
Tan Zhang, Shengchuan Chen, Liang Li, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Yinghong Shi, Guohong Han, Jian Zhou, et al.
Liver Cancer
|
June 23, 2025
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yu Yang, Juxian Sun, Jianqiang Cai, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 78) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 78 results.
Signal Transduction and Targeted Therapy
|
October 5, 2025
Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial
Kang Wang, Jinkai Feng, Hongming Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2024
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Yajin Chen, Chengyou Du, Shunli Shen, et al.
Oncogene
|
February 13, 2024
Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC
Tuo Deng, Jungang Zhao, Yifan Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2023
Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Zhiyuan Bo, Bo Chen, Zhengxiao Zhao, et al.
JCI Insight
|
May 23, 2024
PFKFB3 controls acinar IP3R-mediated Ca2+ overload to regulate acute pancreatitis severity
Tan Zhang, Shengchuan Chen, Liang Li, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Yinghong Shi, Guohong Han, Jian Zhou, et al.
Liver Cancer
|
June 23, 2025
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yu Yang, Juxian Sun, Jianqiang Cai, et al.
Page
of 8